Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702).

Rahbar H, Zhang Z, Chenevert TL, Romanoff J, Kitsch AE, Hanna LG, Harvey SM, Moy L, DeMartini WB, Dogan B, Yang WT, Wang LC, Joe BN, Oh KY, Neal CH, McDonald ES, Schnall MD, Lehman CD, Comstock CE, Partridge SC.

Clin Cancer Res. 2019 Mar 15;25(6):1756-1765. doi: 10.1158/1078-0432.CCR-18-2967. Epub 2019 Jan 15.

2.

Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.

Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA; ACRIN 6678 Research team; MK-0646-008 Research team.

J Nucl Med. 2015 Aug;56(8):1137-43. doi: 10.2967/jnumed.114.147728. Epub 2015 Apr 23.

3.

Contralateral prophylactic mastectomy in the American College of Radiology Imaging Network 6667 trial: effect of breast MR imaging assessments and patient characteristics.

Rahbar H, Hanna LG, Gatsonis C, Mahoney MC, Schnall MD, DeMartini WB, Lehman CD.

Radiology. 2014 Oct;273(1):53-60. doi: 10.1148/radiol.14132029. Epub 2014 Jun 16.

4.

Consequences of false-positive screening mammograms.

Tosteson AN, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, Wang Q, Lindfors K, Pisano ED.

JAMA Intern Med. 2014 Jun;174(6):954-61. doi: 10.1001/jamainternmed.2014.981.

5.

Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.

Hillner BE, Tosteson AN, Tosteson TD, Wang Q, Song Y, Hanna LG, Siegel BA.

J Nucl Med. 2013 Dec;54(12):2024-31. doi: 10.2967/jnumed.113.123430. Epub 2013 Nov 12.

6.

Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.

Hillner BE, Tosteson TD, Tosteson AN, Wang Q, Song Y, Onega T, Hanna LG, Siegel BA.

Med Care. 2013 Apr;51(4):361-7. doi: 10.1097/MLR.0b013e318287d860.

7.

Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial.

Baum JK, Hanna LG, Acharyya S, Mahoney MC, Conant EF, Bassett LW, Pisano ED.

Radiology. 2011 Jul;260(1):61-7. doi: 10.1148/radiol.11101285. Epub 2011 Apr 18.

8.

Frequency of malignancy seen in probably benign lesions at contrast-enhanced breast MR imaging: findings from ACRIN 6667.

Weinstein SP, Hanna LG, Gatsonis C, Schnall MD, Rosen MA, Lehman CD.

Radiology. 2010 Jun;255(3):731-7. doi: 10.1148/radiol.10081712.

9.

PET and PET/CT reports: observations from the National Oncologic PET Registry.

Coleman RE, Hillner BE, Shields AF, Duan F, Merlino DA, Hanna LG, Stine SH, Siegel BA.

J Nucl Med. 2010 Jan;51(1):158-63. doi: 10.2967/jnumed.109.066399. Epub 2009 Dec 15.

Supplemental Content

Loading ...
Support Center